Special Issue

Immunotherapies for Acute Myeloid Leukemia

Message from the Guest Editor

The immunotherapies in cancer treatment have experienced a significant breakthrough in the last few years. T cell activating immunotherapeutic approaches like immune checkpoint inhibition, chimeric antigen receptor T cells (CARs) or bi-specific T cell activating antibodies are becoming increasingly important treatment strategies in different cancer types. In acute myeloid leukemia (AML) after intensive chemotherapy most patients achieve a complete remission, however the overall survival for all AML patients is still relatively low. Immunotherapeutic approaches for AML patients might be options to reduce the relapse rate and therefore improve overall survival. This special issue will focus on immunotherapeutic approaches in AML to begin with on established therapies like the allogeneic stem cell transplantation including new concepts improving the graft versus leukemia effect, but also on new efforts to improve immune responses like adoptive T cell transfer, immune checkpoint inhibition and bispecific antibodies and CAR-T-cell approaches.

Guest Editor

Prof. Dr. Jochen Greiner

- 1. Department of Internal Medicine, Diakonie Hospital Stuttgart, 70176 Stuttgart, Germany
- 2. Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany

Deadline for manuscript submissions

closed (20 December 2018)



Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/13002

Journal of Clinical Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 icm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).